What is the price targets for MedMen Enterprises stock?
According to the issued ratings of 1 analysts in the last year, the consensus rating for MedMen Enterprises stock is Hold based on the current 1 hold rating for MMNFF. The average twelve-month price target for MedMen Enterprises is $0.25 with a high price target of $0.25 and a low price target of $0.25. Learn more
How does MedMen Enterprises (MMNFF) stock rank on Wall Street?
According to the issued ratings of 1 analysts in the last year, the consensus rating for MedMen Enterprises stock is Hold based on the current 1 hold rating for MMNFF. The average twelve-month price target for MedMen Enterprises is $0.25 with a high price target of $0.25 and a low price target of $0.25.
Will MedMen's falling stock price hurt pot stocks?
At the same time, MedMen's falling stock price makes it harder to raise money, as pot stocks tend to accomplish this by raising more equity.
How bad are MedMen's profits?
Its fiscal Q4 2019 revenues came in at $42 million, while its losses increased to $83 million. While it's common for cannabis companies to be unprofitable -- although investors are getting increasingly tired of it -- MedMen's losses are extreme. The company's market cap is just $683 million, but it has only $33.7 million in cash on hand.
Is Mmnff a good stock?
According to the issued ratings of 1 analysts in the last year, the consensus rating for MedMen Enterprises stock is Hold based on the current 1 hold rating for MMNFF. The average twelve-month price prediction for MedMen Enterprises is $0.25 with a high price target of $0.25 and a low price target of $0.25.
Who is MedMen owned by?
MedMen owns and operates 29 retail stores and 6 cultivation facilities. It is currently licensed to expand its footprint to 65 retail locations....MedMen.TypePublicFounderAdam Bierman Andrew ModlinHeadquartersCalifornia, United StatesRevenue$130 Million(2019)Number of employees1,0004 more rows
Is MedMen an OTC stock?
MedMen Subordinate Voting Shares Approved for Inclusion on the OTC and Begin Trading on June 18th Under Ticker Symbol "MMNFF"
What does MedMen enterprises do?
Company Profile MedMen is a cannabis retailer with flagship locations in California, Nevada, Illinois, Florida, and New York.
Is MedMen a good stock to invest in?
USD 0.06 0.0019 3.37% Assuming the 90 days horizon and your above-average risk tolerance, our recommendation regarding MEDMEN ENTERPRISES INC is 'Strong Sell'.
Will Tilray buy MedMen?
Cannabis company Tilray acquires stake Medmen notes in bet on U.S. legalization. Tilray stock jumped nearly 5% in extended trading on Tuesday after announcing an investment in American cannabis retailer Medmen.
Is MedMen being sold?
MedMen to Sell New York Operations for $88 Million; $15 Million Incremental Value. LOS ANGELES--(BUSINESS WIRE)-- MedMen Enterprises Inc.
What is wrong MedMen?
As we have painstakingly pointed out in the past, MedMen's problem was both its balance sheet and cash flow. The company was spending too much money on flagship California locations that were cashflow negative. Additionally, the California assets are generating very little organic growth which is also a big problem.
How much does MedMen make?
The average MedMen salary ranges from approximately $25,898 per year for Market Researcher to $203,574 per year for Regional Director. Average MedMen hourly pay ranges from approximately $12.00 per hour for Harvester to $27.00 per hour for Designer.
Should I buy or sell MedMen Enterprises stock right now?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MedMen Enterprises in the last year. There are currently 1 hold rating for...
What is MedMen Enterprises' stock price forecast for 2022?
1 Wall Street research analysts have issued 1 year price objectives for MedMen Enterprises' shares. Their forecasts range from $0.25 to $0.25. On a...
How has MedMen Enterprises' stock performed in 2022?
MedMen Enterprises' stock was trading at $0.1640 at the start of the year. Since then, MMNFF stock has decreased by 57.3% and is now trading at $0....
Are investors shorting MedMen Enterprises?
MedMen Enterprises saw a increase in short interest in May. As of May 31st, there was short interest totaling 2,657,400 shares, an increase of 25.7...
How were MedMen Enterprises' earnings last quarter?
MedMen Enterprises Inc. (OTCMKTS:MMNFF) issued its earnings results on Monday, February, 15th. The company reported ($0.11) earnings per share (EPS...
Who are MedMen Enterprises' key executives?
MedMen Enterprises' management team includes the following people: Mr. Michael Serruya , Exec. Chairman & CEO (Age 58) Ms. Ana Bowman , Chief F...
Who are some of MedMen Enterprises' key competitors?
Some companies that are related to MedMen Enterprises include Abacus Health Products (ABAHF) , Acreage (ACRGF) , Alliance Growers (ACGWF) , Alt...
What is MedMen Enterprises' stock symbol?
MedMen Enterprises trades on the OTCMKTS under the ticker symbol "MMNFF."
How do I buy shares of MedMen Enterprises?
Shares of MMNFF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBu...
MedMen Announces Resignation of Chief Revenue Officer
MedMen wins six month grace period on debt
LOS ANGELES, February 12, 2022--MedMen Announces Resignation of Chief Revenue Officer
MedMen Enterprises (OTCMKTS:MMNFF) Price Target and Consensus Rating
Cannabis company MedMen Enterprises Inc. on Wednesday announced a six month grace period for a $114.3 million commercial loan agreement issued on Oct. 1, 2018. MedMen CEO Michael Serruya said the company will use the time to "realize fair value for significant assets that are no longer core to our market strategy," according to a statement.
Analyst Price Target Consensus
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy).
Analyst Ratings By Month
Sign-up to receive the latest news and ratings for MMNFF and its competitors with MarketBeat's FREE daily newsletter.
Average Share Price and Price Target by Month
The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
MedMen Enterprises (OTCMKTS:MMNFF) Analyst Ratings Frequently Asked Questions
The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target.
How much money did Medmen make in 2019?
According to the issued ratings of 1 analysts in the last year, the consensus rating for MedMen Enterprises stock is Hold based on the current 1 hold rating for MMNFF. The average twelve-month price target for MedMen Enterprises is $0.25 with a high price target of $0.25 and a low price target of $0.25. Learn more on MMNFF's analyst rating history
Where are Medmen stores located?
In short, MedMen is spending far more than it's making. Its fiscal Q4 2019 revenues came in at $42 million, while its losses increased to $83 million. While it's common for cannabis companies to be unprofitable -- although investors are getting increasingly tired of it -- MedMen's losses are extreme.
What would happen if Pharmacann went through?
MedMen's main territory is in California, with a secondary presence in Florida, Nevada, and New York. Currently, the company owns 17 retail licenses for California, but since it already operates 13 stores in the state, MedMen has only limited room to add dispensaries in the area. Even with the stores MedMen already has in place, ...
Does Medmen have breathing room?
If the PharmaCann deal had gone through, MedMen would have expanded its operational presence across the country, becoming one of the larger multistate operators. However, now that this isn't a possibility, the company will need to figure out what to do with its current operations.
There's more to this deal than surface-scratching headlines suggest
Unlike other companies such as Canopy Growth, which has billions of dollars of cash to help cover future growth expenses, MedMen has frighteningly little financial breathing room. Investors need to ask themselves where this money is going.
Upscale dispensary chain MedMen lands a major investment partner
A Fool since 2010, and a graduate from UC San Diego with a B.A. in Economics, Sean specializes in the healthcare sector and investment planning. You'll often find him writing about Obamacare, marijuana, drug and device development, Social Security, taxes, retirement issues and general macroeconomic topics of interest. Follow @AMCScam
1. There was a connection between GGP and MedMen before this deal
Roughly 10 days ago, on March 22, U.S.-based upscale vertically integrated cannabis dispensary MedMen Enterprises ( OTC:MMNFF) got a large capital infusion of its own.
2. Ultimately, it could still be dilutive to investors
What you might not realize about Gotham Green Partners is that co-founder and managing member Jason Adler is also on the board of directors for Cronos Group ( NASDAQ:CRON) as a member of the audit committee and compensation committee.
3. This capital will go quickly
Secondly, although it looks as if MedMen just solidified its near-term cash position, it's important for investors to understand that this could be just a glorified means of diluting its shareholders. As noted in MedMen's press release:
4. MedMen still has a long way to go to differentiate itself in the dispensary space
Don't think for a moment that $250 million in capital is going to last MedMen for all that long. Even though it's an eye-popping investment figure in the cannabis industry, opening new retail locations and making acquisitions have been eating up MedMen's capital at an extraordinary pace.